RJA
TGTX icon

Raymond James & Associates’s TG Therapeutics TGTX Stock Holding History

Raymond James & Associates’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,700
Closed -$273K – 4107
2020
Q4 		$273K Buy
+21,700
New +$733K ﹤0.01% 3182

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's TGTX Position: Q3 2024 in Review

Raymond James & Associates increased its TG Therapeutics (TGTX) stake by 36% in Q3 2024, buying an estimated $982K and bringing the position to 170,160 shares worth $3.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1811.

Raymond James & Associates first reported a position in TGTX in Q1 2015 and has held it in 37 quarters since. The position peaked at $10.8M in Q4 2020. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Raymond James & Associates held 170,160 shares of TG Therapeutics worth $3.98M as of Q3 2024.
  • Raymond James & Associates bought 44,972 TG Therapeutics shares in Q3 2024, an estimated $982K.
  • TG Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1811 holding.
  • Raymond James & Associates first reported a position in TG Therapeutics in Q1 2015 and has held it in 37 quarters since.
  • Raymond James & Associates's TG Therapeutics position peaked at $10.8M in Q4 2020.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.